Impact Factor
3.15
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.42
3,986 total citations
h5-index
66
h5 depth signal
Cited share
28.7%
836 of 2,910
Total citations
3,986
Citation footprint
Metric signal
1.37
External metric anchor
Self-citation
5.5%
219 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
2,613
United Kingdom
2,366
Italy
1,599
Spain
1,376
Belgium
1,222
Citing Fields of Research
Inflammatory Bowel Diseases & Infections
13,563
Immunology
1,462
Digestive Disorders
1,315
Auto-Inflammatory Disorders
388
Epithelial Barriers
305
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
19,405
Articles tracked across the journal lifetime
Indexed publication set
2,910
836 cited publications
Last 12 months
1,763
146.9 publications/month
Open access share
4.6%
81 OA publications in the last year
Leading citing country
United States
2,613 citing publications
Leading citing field
Inflammatory Bowel Diseases & Infections
13,563 citing publications
Latest tracked publication
9 October 2026
10 recent records available
Coverage & Indexing History
v4n1, Feb. 2010-
v4n1, Feb. 2010-
Research Focus & Classification
Indexed Subjects
Inflammatory Bowel Diseases & Infections
Issuing & Sponsoring Bodies
Contributor
European Crohn's and Colitis Organisation
Broad Categories
Gastroenterology
Inflammatory Bowel Diseases & Infections
MeSH Descriptors
Inflammatory Bowel Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1093/ecco-jcc/jjag154
Open DOI
Safety and tolerability of anti-toll-like receptor 3, monoclonal antibody PRV-300 in patients with moderate-to-severe ulcerative colitis: a randomized phase 1B clinical trial (PULSE)
Background & Aims: PRV-300 is a fully human IgG4κ monoclonal antibody that binds the extracellular domain of human toll-like receptor 3, which is overexpressed in the inflamed colonic epithelium in patients with inflammatory bowel diseas...
02
03
DOI 10.1093/ecco-jcc/jjag147
Open DOI
Tofacitinib 20 vs 30 mg in acute severe ulcerative colitis: a double-blind randomized controlled trial
Background & Aims: Tofacitinib has emerged as a promising therapy for acute severe ulcerative colitis (ASUC) due to its rapid onset of action. We compared the efficacy and safety of tofacitinib 20 mg/day vs 30 mg/day, both administered w...
04
DOI 10.1093/ecco-jcc/jjag159
Open DOI
Etrasimod reduces circulating and mucosal inflammatory lymphocyte populations and alters innate immune and non-immune cell signatures in intestinal mucosa: ELEVATE UC phase 3 clinical data
Background and Aims: Innate and adaptive immune cell dysregulation contributes to ulcerative colitis pathogenesis. The sphingosine 1-phosphate receptor modulator etrasimod showed efficacy in ulcerative colitis treatment in Phase 3 ELEVAT...
05
DOI 10.1093/ecco-jcc/jjag135
Open DOI
Challenges and opportunities facing inflammatory bowel disease in Sub-Saharan Africa: towards a contextually relevant research and practice agenda
Inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, has traditionally been considered a disease of Western, industrialized countries. Over the past few decades, however, many Sub-Saharan African (SSA) cou...
06
DOI 10.1093/ecco-jcc/jjag155
Open DOI
Contemporary multicentre validation and comparative performance of Day 1 prognostic scores in acute severe ulcerative colitis
Background and Aims: Early identification of steroid non-response in acute severe ulcerative colitis (ASUC) is critical to guide timely escalation of therapy. Several Day 1 prognostic scores have been proposed, but their comparative perf...
07
DOI 10.1093/ecco-jcc/jjag146
Open DOI
Plasma lipopolysaccharide-binding protein (LBP), a proxy for intestinal permeability, relates to clinicopathological and immunological disease activity in inflammatory bowel disease patients at diagnosis and during disease course
Background and Aims: Intestinal barrier healing is the treatment goal in ulcerative colitis (UC) and Crohn’s disease (CD). Despite this, systematic analyses of the relationship between intestinal permeability and clinicopathological and ...
08
DOI 10.1093/ecco-jcc/jjag145
Open DOI
Epidemiology of inflammatory bowel disease in the Middle East and North Africa: a multinational, tertiary care registry (MIRAGE) study
Background and Aims: Inflammatory bowel disease (IBD) is increasing in the Middle East and North Africa (MENA), yet region-specific evidence on phenotype and treatment patterns remains limited. We aimed to characterize IBD epidemiology, ...
09
DOI 10.1093/ecco-jcc/jjag134
Open DOI
Real-world effectiveness and safety of risankizumab induction and maintenance therapy in pediatric patients with Crohn’s disease: a multicenter retrospective analysis
Background & Aims: Risankizumab is approved for adults with Crohn’s disease (CD); pediatric data are limited. We evaluated real-world effectiveness, durability, safety, and dosing in children with CD. Methods: Retrospective, global multi...
10
DOI 10.1093/ecco-jcc/jjag141
Open DOI
Distinct intestinal eosinophil subsets in ulcerative colitis and their modulation by advanced inflammatory bowel disease therapies
Background and aims: Despite the importance of eosinophils in histologic scoring systems of ulcerative colitis (UC), the impact of advanced therapies on eosinophils is poorly understood. Additionally, data regarding distinct eosinophil s...
Bibliographical & Catalog Notes
Description based on: Vol. 2, issue 2 (June 2008); title from title page.
Also issued online.
Between 2007-2010: Journal of Crohn's and colitis supplements 1873-9954 (DLC) 2008243519 (OCoLC)228620170 (DNLM)101473868.